| 1. | dwaysche | |
| 2. | kirkskraft | |
| 3. | lieselloveszach | |
| 4. | 4tokoma4tokoma | |
| 5. | nlanas2sk051p |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | lieselloveszach 06/28/2018 Cantor Fitzgerald reiterates Buy rating, $42 PT |
| 2. | 4tokoma4tokoma 02/22/2018 We should be over 40 by now |
| 3. | lieselloveszach 03/06/2018 Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine |
| 4. | lieselloveszach 10/23/2018 Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist |
| 5. | kirkskraft 02/22/2018 Nice boost |
| 6. | dwaysche 02/21/2018 Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists |
| 7. | 4tokoma4tokoma 01/09/2018 Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet |
| 8. | lieselloveszach 06/08/2018 Piper Jaffray sets PT at $48 |
| 9. | kirkskraft 02/22/2018 Will be in the 40 range soon. |
| 10. | 4tokoma4tokoma 01/10/2019 Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
Biohaven Pharmaceutical Holding Company Ltd.
- BHVN
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.